B.C. Supreme Court Certifies Class-Action Lawsuit Against Opioid Manufacturers with Potential Impact on 49,000 Deaths

British Columbia's attorney general, Niki Sharma, announced that the B.C. Supreme Court has officially certified the province's class-action lawsuit against opioid manufacturers and distributors. This development allows B.C. to act as a representative plaintiff for other Canadian governments in seeking to recover healthcare costs associated with opioid-related diseases, which are alleged to stem from the industry's practices.

Sharma emphasized that this ruling underscores B.C.'s commitment to holding pharmaceutical companies accountable for their involvement in the ongoing opioid crisis, a situation declared a public health emergency in April 2016. The court had previously affirmed the constitutionality of a law enabling B.C. to pursue this class-action lawsuit on behalf of other governments, with the majority of the top court agreeing that B.C.'s law respects the legislative authority of provinces and territories, allowing them the option to opt out.

The attorney general described the certification as a "significant milestone" in a legal battle that began in 2018. "Our goal was clear: to recover the healthcare costs of treating opioid-related harms and to hold manufacturers and distributors accountable for their allegedly deceptive marketing practices," she stated. Sharma also noted that the pharmaceutical companies involved have attempted various strategies to delay the lawsuit, but the recent court ruling indicates these efforts were unsuccessful.

The latest statistics from the B.C. Coroners Service report 1,925 overdose deaths in the first ten months of the previous year—a 9% decrease from 2023. Nationally, over 49,000 opioid toxicity deaths have been reported from January 2016 to June 2024, highlighting the severe impact of the crisis across Canada.

Federal Mental Health and Addictions Minister Ya'ara Saks expressed her support for the lawsuit, stating that Canada remains committed to joining this legal action. "Our work to end the predatory practices of the pharmaceutical industry continues," she said.

As this lawsuit progresses, it aims not only to recover costs but also to promote accountability within the pharmaceutical sector for its role in the opioid epidemic.